Module

Clinical Studies of Integrase Inhibitors: A Comprehensive Review

Source: The Role of Integrase Inhibitors in HIV Management

Clinical Studies of Integrase Inhibitors: A Comprehensive Review

Faculty:

Martin Markowitz, MD

CME CREDIT INFORMATION

Release Date: 04/22/08

Expiration Date: 04/21/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the results of proof-of-concept clinical trials concerning the use of the integrase inhibitors raltegravir and elvitegravir as monotherapy
Describe the results of clinical trials involving the use of raltegravir and elvitegravir in combination therapy regimens in treatment-naive and treatment-experienced patients
Discuss the role of additional active agents in the optimized background regimens of raltegravir- and elvitegravir-containing antiretroviral therapy regimens

Topics covered include:

Introduction
Raltegravir Monotherapy Proof-of-Concept Studies
Elvitegravir Monotherapy Proof-of-Concept Studies
Raltegravir Combination Therapy in Treatment-Naive Subjects
Raltegravir Combination Antiretroviral Therapy in Treatment-Experienced Subjects
Elvitegravir Combination Antiretroviral Therapy in Treatment-Experienced Subjects
Integrase Inhibitor Resistance
Summary

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.